Nasdaq · CIK 0001070081
PTCT PTC THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing 3 d ago. Close $64.70 on Oct 9, 2026, +4% from the 52-week low and -28% from the high.
Last 90 days
Net insider value
-$3.8M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
5
$3.8M by 3 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
PTCTOct 9, 2026 · close 64.70
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at PTC THERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Michael Schmertzler director sell | $158k 2,500 shares | -0% | +2% from low-29% from high | |
| 6Weak | Mark Elliott Boulding EXEC. VP AND CLO sell | $133k 2,073 shares | -2% | +2% from low-29% from high | |
| 27Weak | Glenn Steele Jr Md Phd director sell | $782k 12,000 shares | -35% | +6% from low-28% from high | |
| 28Weak | Michael Schmertzler director sell | $1.3M 20,000 shares | -2% | +17% from low-25% from high | |
| 20Weak | Michael Schmertzler director sell | $1.4M 20,000 shares | -1% | +17% from low-25% from high | |
| 15Weak | Mark Elliott Boulding EXEC. VP AND CLO sell | $2.9M 47,249 shares | -39% | +89% from low0% from high | |
| 0Weak | Mark Elliott Boulding EXEC. VP AND CLO sell | $137k 2,813 shares | -3% | +51% from low-15% from high | |
| 0Weak | Mark Elliott Boulding EXEC. VP AND CLO sell | $130k 2,812 shares | -3% | +40% from low-21% from high | |
| 16Weak | Matthew B. Klein CHIEF EXECUTIVE OFFICER sell | $137k 2,804 shares | -1% | +49% from low-16% from high | |
| 1Weak | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER sell | $42k 897 shares | -1% | +50% from low-15% from high | |
| 16Weak | Mark Elliott Boulding EXEC. VP AND CLO sell | $827k 15,521 shares | -13% | +66% from low-3% from high | |
| 33Weak | Mark Elliott Boulding EXEC. VP AND CLO sell | $4.0M 75,420 shares | -51% | +63% from low-5% from high | |
| 38Weak | Allan Steven Jacobson director sell | $63k 1,230 shares | -6% | +61% from low-6% from high | |
| 21Weak | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER sell | $148k 2,946 shares | -3% | +56% from low-3% from high | |
| 21Weak | Mark Elliott Boulding EXEC. VP AND CLO sell | $148k 2,947 shares | -3% | +56% from low-3% from high | |
| 19Weak | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER sell | $88k 1,757 shares | -2% | +56% from low-3% from high | |
| 27Weak | Pierre Gravier CHIEF FINANCIAL OFFICER sell | $117k 2,335 shares | -3% | +56% from low-3% from high | |
| 36Weak | Matthew B. Klein CHIEF EXECUTIVE OFFICER sell | $390k 7,792 shares | -3% | +56% from low-3% from high | |
| 21Weak | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER sell | $134k 2,979 shares | -3% | +38% from low-14% from high | |
| 21Weak | Mark Elliott Boulding EXEC. VP AND CLO sell | $159k 3,541 shares | -3% | +38% from low-14% from high | |
| 19Weak | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER sell | $90k 2,008 shares | -2% | +38% from low-14% from high | |
| 32Weak | Matthew B. Klein CHIEF EXECUTIVE OFFICER sell | $204k 4,544 shares | -2% | +38% from low-14% from high | |
| 35Weak | Matthew B. Klein CHIEF EXECUTIVE OFFICER sell | $374k 8,279 shares | -4% | +40% from low-13% from high | |
| 40Moderate | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER sell | $3.7M 71,610 shares | -81% | - | |
| 40Moderate | Mark Elliott Boulding EXEC. VP AND CLO sell | $5.0M 95,908 shares | -102% | - | |
| 29Weak | Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER sell | $922k 17,800 shares | -32% | - | |
| 40Moderate | Jerome B Zeldis director sell | $1.2M 24,000 shares | -91% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Michael Schmertzler director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,447 | $63.38 | $155k | 1,294,147 | 3 d ago |
| Oct 7, 2026 | Michael Schmertzler director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -53 | $63.95 | $3,389 | 1,294,094 | 3 d ago |
| Oct 5, 2026 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +1,638 | $39.42 | $65k | 106,910 | 5 d ago |
| Oct 5, 2026 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -1,638 | $64.03 | $105k | 105,272 | 5 d ago |
| Oct 6, 2026 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +435 | $39.42 | $17k | 105,707 | 5 d ago |
| Oct 6, 2026 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -435 | $64.16 | $28k | 105,272 | 5 d ago |
| Oct 5, 2026 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,638 | $0.00 | $0 | 2,894 | 5 d ago |
| Oct 6, 2026 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -435 | $0.00 | $0 | 2,459 | 5 d ago |
| Sep 30, 2026 | Glenn Steele Jr Md Phd director | MOption exercise Common Stock10b5-1 | +12,000 | $11.23 | $135k | 34,500 | 10 d ago |
| Sep 30, 2026 | Glenn Steele Jr Md Phd director | SOpen-market sale Common Stock10b5-1 | -12,000 | $65.16 | $782k | 22,500 | 10 d ago |
| Sep 30, 2026 | Glenn Steele Jr Md Phd director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,000 | $0.00 | $0 | 0 | 10 d ago |
| Sep 16, 2026 | Michael Schmertzler director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,994 | $66.58 | $199k | 1,313,600 | 24 d ago |
| Sep 16, 2026 | Michael Schmertzler director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -7,006 | $67.35 | $472k | 1,306,594 | 24 d ago |
| Sep 17, 2026 | Michael Schmertzler director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -9,624 | $67.83 | $653k | 1,296,970 | 24 d ago |
| Sep 17, 2026 | Michael Schmertzler director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -376 | $68.45 | $26k | 1,296,594 | 24 d ago |
| Sep 9, 2026 | Michael Schmertzler director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -9,428 | $67.79 | $639k | 1,327,166 | 31 d ago |
| Sep 9, 2026 | Michael Schmertzler director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -572 | $68.67 | $39k | 1,326,594 | 31 d ago |
| Sep 10, 2026 | Michael Schmertzler director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -10,000 | $67.34 | $673k | 1,316,594 | 31 d ago |
| Sep 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +17,838 | $38.10 | $680k | 121,739 | Sep 15, 2025 |
| Sep 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -17,838 | $61.00 | $1.1M | 103,901 | Sep 15, 2025 |
| Sep 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +2,356 | $38.10 | $90k | 106,257 | Sep 15, 2025 |
| Sep 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -2,356 | $61.00 | $144k | 103,901 | Sep 15, 2025 |
| Sep 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +2,470 | $38.10 | $94k | 106,371 | Sep 15, 2025 |
| Sep 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -2,470 | $61.00 | $151k | 103,901 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +22,661 | $38.10 | $863k | 126,562 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -22,117 | $61.33 | $1.4M | 104,445 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -544 | $62.09 | $34k | 103,901 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +1,019 | $38.10 | $39k | 104,920 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -1,019 | $61.31 | $62k | 103,901 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +905 | $38.10 | $34k | 104,806 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -905 | $61.21 | $55k | 103,901 | Sep 15, 2025 |
| Sep 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,838 | $0.00 | $0 | 36,162 | Sep 15, 2025 |
| Sep 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,356 | $0.00 | $0 | 33,806 | Sep 15, 2025 |
| Sep 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,470 | $0.00 | $0 | 31,336 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -22,661 | $0.00 | $0 | 8,675 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,019 | $0.00 | $0 | 7,656 | Sep 15, 2025 |
| Sep 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -905 | $0.00 | $0 | 6,751 | Sep 15, 2025 |
| Aug 15, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +2,813 | $25.69 | $72k | 106,714 | Aug 19, 2025 |
| Aug 15, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -2,813 | $48.58 | $137k | 103,901 | Aug 19, 2025 |
| Aug 15, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,813 | $0.00 | $0 | 24,899 | Aug 19, 2025 |
| May 15, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +1,929 | $25.69 | $50k | 105,830 | May 19, 2025 |
| May 15, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -1,929 | $46.18 | $89k | 103,901 | May 19, 2025 |
| May 16, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +883 | $25.69 | $23k | 104,784 | May 19, 2025 |
| May 16, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -883 | $46.02 | $41k | 103,901 | May 19, 2025 |
| May 15, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,929 | $0.00 | $0 | 28,595 | May 19, 2025 |
| May 16, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -883 | $0.00 | $0 | 27,712 | May 19, 2025 |
| Apr 22, 2025 | Matthew B. Klein CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -2,804 | $48.74 | $137k | 273,234 | Apr 24, 2025 |
| Apr 2, 2025 | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -897 | $46.95 | $42k | 75,997 | Apr 4, 2025 |
| Mar 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +13,126 | $33.02 | $433k | 117,027 | Mar 14, 2025 |
| Mar 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -13,126 | $53.31 | $700k | 103,901 | Mar 14, 2025 |
| Mar 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +2,395 | $33.02 | $79k | 106,296 | Mar 14, 2025 |
| Mar 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -2,395 | $53.23 | $127k | 103,901 | Mar 14, 2025 |
| Mar 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -13,126 | $0.00 | $0 | 0 | Mar 14, 2025 |
| Mar 12, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,395 | $0.00 | $0 | 0 | Mar 14, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +45,392 | $33.02 | $1.5M | 149,293 | Mar 12, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -45,392 | $53.15 | $2.4M | 103,901 | Mar 12, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +11,398 | $33.02 | $376k | 115,299 | Mar 12, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -11,398 | $53.12 | $605k | 103,901 | Mar 12, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +11,249 | $25.69 | $289k | 115,150 | Mar 12, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -3,487 | $52.24 | $182k | 111,663 | Mar 12, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -7,762 | $53.05 | $412k | 103,901 | Mar 12, 2025 |
| Mar 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +5,662 | $33.02 | $187k | 109,563 | Mar 12, 2025 |
| Mar 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -5,662 | $53.02 | $300k | 103,901 | Mar 12, 2025 |
| Mar 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Common Stock10b5-1 | +1,719 | $33.02 | $57k | 105,620 | Mar 12, 2025 |
| Mar 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -1,719 | $53.01 | $91k | 103,901 | Mar 12, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -45,392 | $0.00 | $0 | 18,788 | Mar 12, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,398 | $0.00 | $0 | 4,114 | Mar 12, 2025 |
| Mar 10, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,249 | $0.00 | $0 | 33,751 | Mar 12, 2025 |
| Mar 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,662 | $0.00 | $0 | 13,126 | Mar 12, 2025 |
| Mar 11, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,719 | $0.00 | $0 | 2,395 | Mar 12, 2025 |
| Mar 4, 2025 | Allan Steven Jacobson director | SOpen-market sale Common Stock | -1,230 | $51.52 | $63k | 19,118 | Mar 6, 2025 |
| Feb 19, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | SOpen-market sale Common Stock10b5-1 | -1,300 | $50.10 | $65k | 101,931 | Feb 21, 2025 |
| Feb 19, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -1,333 | $50.10 | $67k | 105,515 | Feb 21, 2025 |
| Feb 19, 2025 | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -795 | $50.10 | $40k | 77,856 | Feb 21, 2025 |
| Feb 19, 2025 | Pierre Gravier CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,168 | $50.10 | $59k | 75,603 | Feb 21, 2025 |
| Feb 19, 2025 | Matthew B. Klein CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -3,897 | $50.10 | $195k | 279,933 | Feb 21, 2025 |
| Feb 20, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -1,614 | $50.12 | $81k | 103,901 | Feb 21, 2025 |
| Feb 20, 2025 | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -962 | $50.12 | $48k | 76,894 | Feb 21, 2025 |
| Feb 20, 2025 | Pierre Gravier CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,167 | $50.12 | $58k | 74,436 | Feb 21, 2025 |
| Feb 20, 2025 | Matthew B. Klein CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -3,895 | $50.12 | $195k | 276,038 | Feb 21, 2025 |
| Feb 19, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -34 | $50.10 | $1,703 | 5,941 | Feb 21, 2025 |
| Feb 20, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | SOpen-market sale Common Stock10b5-1 | -1,578 | $50.12 | $79k | 100,353 | Feb 21, 2025 |
| Feb 20, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -34 | $50.12 | $1,704 | 5,907 | Feb 21, 2025 |
| Jan 7, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | SOpen-market sale Common Stock10b5-1 | -1,265 | $45.34 | $57k | 104,783 | Jan 10, 2025 |
| Jan 7, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -1,543 | $45.34 | $70k | 108,846 | Jan 10, 2025 |
| Jan 7, 2025 | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -810 | $45.34 | $37k | 79,849 | Jan 10, 2025 |
| Jan 7, 2025 | Matthew B. Klein CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -2,142 | $45.34 | $97k | 286,232 | Jan 10, 2025 |
| Jan 8, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | SOpen-market sale Common Stock10b5-1 | -1,998 | $44.50 | $89k | 106,848 | Jan 10, 2025 |
| Jan 8, 2025 | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,198 | $44.50 | $53k | 78,651 | Jan 10, 2025 |
| Jan 8, 2025 | Matthew B. Klein CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -2,402 | $44.50 | $107k | 283,830 | Jan 10, 2025 |
| Jan 7, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -55 | $45.34 | $2,494 | 6,082 | Jan 10, 2025 |
| Jan 8, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | SOpen-market sale Common Stock10b5-1 | -1,552 | $44.50 | $69k | 103,231 | Jan 10, 2025 |
| Jan 8, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -107 | $44.50 | $4,762 | 5,975 | Jan 10, 2025 |
| Jan 3, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | AGrant or award Common Stock | +19,000 | $0.00 | $0 | 106,048 | Jan 7, 2025 |
| Jan 3, 2025 | Matthew B. Klein CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +70,000 | $0.00 | $0 | 288,374 | Jan 7, 2025 |
| Jan 3, 2025 | Allan Steven Jacobson director | AGrant or award Common Stock | +4,000 | $0.00 | $0 | 20,348 | Jan 7, 2025 |
| Jan 3, 2025 | Pierre Gravier CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +22,500 | $0.00 | $0 | 76,771 | Jan 7, 2025 |
| Jan 3, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | AGrant or award Common Stock | +18,000 | $0.00 | $0 | 110,389 | Jan 7, 2025 |
| Jan 3, 2025 | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 80,659 | Jan 7, 2025 |
| Jan 3, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | AGrant or award Common Stockindirect: By Spouse | +715 | $0.00 | $0 | 6,137 | Jan 7, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER
- Mark Elliott BouldingEXEC. VP AND CLO
- Lee Scott GoldenEVP & CHIEF MEDICAL OFFICER
- Pierre GravierCHIEF FINANCIAL OFFICER
- Allan Steven Jacobsondirector
- Matthew B. KleinCHIEF EXECUTIVE OFFICER
- Michael Schmertzlerowner, director
- Glenn Steele Jr Md Phddirector
- Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER
- Jerome B Zeldisdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.